601607 上海医药
午间休市 01-30 11:29:58
资讯
新帖
简况
上海医药：关于公司控股股东及一致行动人的增持计划，目前正在有序实施中
证券日报 · 01-29 21:19
上海医药：关于公司控股股东及一致行动人的增持计划，目前正在有序实施中
上海医药(02607)：七味防己黄芪颗粒获得临床试验批准通知书
智通财经 · 01-29 17:37
上海医药(02607)：七味防己黄芪颗粒获得临床试验批准通知书
每周股票复盘：上海医药（601607）B023细胞注射液获临床试验批准
证券之星 · 01-25
每周股票复盘：上海医药（601607）B023细胞注射液获临床试验批准
上海医药最新公告：马来酸阿伐曲泊帕片获得批准生产
证券之星 · 01-23
上海医药最新公告：马来酸阿伐曲泊帕片获得批准生产
上海医药：普瑞巴林胶囊获得药品注册证书
南方财经网 · 01-23
上海医药：普瑞巴林胶囊获得药品注册证书
上海医药：目前公司整体运营规范有序，各项业务稳步推进
证券日报 · 01-20
上海医药：目前公司整体运营规范有序，各项业务稳步推进
上海医药：上药生物B023细胞注射液临床试验获批准
财中社 · 01-20
上海医药：上药生物B023细胞注射液临床试验获批准
每周股票复盘：上海医药（601607）收购财务公司10%股权完成
证券之星 · 01-18
每周股票复盘：上海医药（601607）收购财务公司10%股权完成
上海医药：已完成收购上实集团财务公司10%股权 持股权比例增加至40%
中金财经 · 01-15
上海医药：已完成收购上实集团财务公司10%股权 持股权比例增加至40%
上海医药(02607)完成收购财务公司10%股权
智通财经 · 01-13
上海医药(02607)完成收购财务公司10%股权
上海医药(601607.SH)：硫酸艾沙康唑原料药上市申请获得批准
智通财经 · 01-13
上海医药(601607.SH)：硫酸艾沙康唑原料药上市申请获得批准
每周股票复盘：上海医药（601607）溴吡斯的明口服液获批生产
证券之星 · 01-11
每周股票复盘：上海医药（601607）溴吡斯的明口服液获批生产
上海医药：溴吡斯的明口服溶液获得批准生产
每日经济新闻 · 01-09
上海医药：溴吡斯的明口服溶液获得批准生产
每周股票复盘：云南白药（000538）预计2026年与上海医药关联交易达19亿元
证券之星 · 01-02
每周股票复盘：云南白药（000538）预计2026年与上海医药关联交易达19亿元
上海医药拟与云南白药续签关联交易协议，2026年双向交易额上限19亿元
中金财经 · 2025-12-31
上海医药拟与云南白药续签关联交易协议，2026年双向交易额上限19亿元
上海医药拟与云南白药续签19亿元上限关联交易协议，销售采购双向合作
财中社 · 2025-12-29
上海医药拟与云南白药续签19亿元上限关联交易协议，销售采购双向合作
上海医药拟续签云南白药框架协议 2026年销售上限12亿元、采购上限7亿元
美股速递 · 2025-12-29
上海医药拟续签云南白药框架协议 2026年销售上限12亿元、采购上限7亿元
上实集团财务公司股权变更获批 上海医药合计持股比例达40%
中国网财经 · 2025-12-29
上实集团财务公司股权变更获批 上海医药合计持股比例达40%
每周股票复盘：上海医药（601607）每股派现0.12元
证券之星 · 2025-12-28
每周股票复盘：上海医药（601607）每股派现0.12元
建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等
证券之星 · 2025-12-26
建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.33,"timestamp":1769743798000,"preClose":17.42,"halted":0,"volume":10922700,"delay":0,"changeRate":-0.0052,"floatShares":2789000000,"shares":3708000000,"eps":1.5224,"marketStatus":"午间休市","change":-0.09,"latestTime":"01-30 11:29:58","open":17.41,"high":17.45,"low":17.25,"amount":190000000,"amplitude":0.0115,"askPrice":17.33,"askSize":20,"bidPrice":17.31,"bidSize":44,"shortable":0,"etf":0,"ttmEps":1.5224,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769749200000},"marketStatusCode":3,"adr":0,"adjPreClose":17.42,"symbolType":"stock","openAndCloseTimeList":[[1769736600000,1769743800000],[1769749200000,1769756400000]],"highLimit":19.16,"lowLimit":15.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.85,"roa":"--","peRate":11.383342,"roe":"6.96%","epsLYR":1.23,"committee":0.636392,"marketValue":64266000000,"turnoverRate":0.0039,"status":1,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.89,"timestamp":1769745900006,"preClose":11.95,"halted":0,"volume":802700,"delay":0,"premium":"-38.95"},"floatMarketCap":48337000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2607080136","title":"上海医药：关于公司控股股东及一致行动人的增持计划，目前正在有序实施中","url":"https://stock-news.laohu8.com/highlight/detail?id=2607080136","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607080136?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:19","pubTimestamp":1769692760,"startTime":"0","endTime":"0","summary":"证券日报网讯1月29日，上海医药在互动平台回答投资者提问时表示，关于公司控股股东及一致行动人的增持计划，目前正在有序实施中。公司始终严格遵守信息披露的相关法律法规及监管要求，若增持进展达到规定的披露标准，公司将及时履行信息披露义务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601293635588171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","02607","BK0196","BK0028","BK0097","BK0183","BK0209","BK0012","BK0188","BK1197","601607","BK0099","BK0175","BK0187","BK0184"],"gpt_icon":0},{"id":"2607870796","title":"上海医药(02607)：七味防己黄芪颗粒获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607870796","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607870796?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:37","pubTimestamp":1769679444,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，上海医药集团股份有限公司下属正大青春宝药业有限公司研发的“七味防己黄芪颗粒” 收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。七味防己黄芪颗粒为公司研发的中药1.1类创新药，截至本公告披露日，该产品尚未在国内外上市。本次七味防己黄芪颗粒获得临床试验批准通知书，对公司经营情况无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","02607","BK0099","BK0196","BK0028","BK0187","BK1197","BK0184","BK0183","BK0097","601607","BK0209","BK0012","BK0188","BK0175"],"gpt_icon":0},{"id":"2606234565","title":"每周股票复盘：上海医药（601607）B023细胞注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234565","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234565?lang=zh_cn&edition=full","pubTime":"2026-01-25 01:30","pubTimestamp":1769275832,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，上海医药报收于17.48元，较上周的17.36元上涨0.69%。本周关注点公司公告汇总：B023细胞注射液获临床试验批准，为I类创新型生物制品。公司公告汇总上海医药集团股份有限公司下属上药生物治疗自主研发的B023细胞注射液收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展针对不可手术的经标准治疗失败的、无有效治疗方式的局部晚期或转移性实体瘤的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","BK0209","BK0012","BK0020","BK0175","BK0188","BK1197","BK0097","BK0183","BK0099","BK0184","BK0028","02607","601607"],"gpt_icon":0},{"id":"2605131422","title":"上海医药最新公告：马来酸阿伐曲泊帕片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2605131422","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605131422?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:47","pubTimestamp":1769154461,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属上海上药信谊药厂有限公司的马来酸阿伐曲泊帕片收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。该药品适用于慢性肝病相关血小板减少症的成年患者以及既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症（ITP）成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300020092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","02607","BK0028","BK0012","601607","BK0183","BK0187","BK0209","BK0175","BK0188","BK0099","BK0097","BK0196","BK1197","BK0184"],"gpt_icon":0},{"id":"2605422372","title":"上海医药：普瑞巴林胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605422372","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605422372?lang=zh_cn&edition=full","pubTime":"2026-01-23 15:37","pubTimestamp":1769153830,"startTime":"0","endTime":"0","summary":"【上海医药：普瑞巴林胶囊获得药品注册证书】上海医药公告，公司全资子公司常州制药厂有限公司收到新加坡食品药品监督管理局（HSA）签发的普瑞巴林胶囊《药品注册证书》。该产品用于治疗带状疱疹后神经痛、糖尿病外周神经痛、纤维肌痛和脊髓损伤引起的神经性疼痛以及癫痫的辅助治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628827261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0183","BK0184","BK0188","BK0209","BK0187","BK0099","BK0028","02607","BK0020","BK0196","601607","BK1197","BK0012","BK0097"],"gpt_icon":0},{"id":"2604155192","title":"上海医药：目前公司整体运营规范有序，各项业务稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2604155192","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604155192?lang=zh_cn&edition=full","pubTime":"2026-01-20 19:09","pubTimestamp":1768907379,"startTime":"0","endTime":"0","summary":"证券日报网讯1月20日，上海医药在互动平台回答投资者提问时表示，目前公司整体运营规范有序，各项业务稳步推进，业绩稳健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624852016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0196","BK0209","BK0012","BK0020","BK0175","BK0188","BK1197","BK0097","BK0183","BK0099","BK0184","BK0028","02607","601607"],"gpt_icon":0},{"id":"2604198356","title":"上海医药：上药生物B023细胞注射液临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604198356","media":"财中社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604198356?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:09","pubTimestamp":1768896570,"startTime":"0","endTime":"0","summary":"1月20日，上海医药（601607/02607）发布公告，近日公司旗下的上药生物治疗自主研发的B023细胞注射液收到国家药监局核准签发的《药物临床试验批准通知书》。该项目旨在针对不可手术的经标准治疗失败的、无有效治疗方式的局部晚期或转移性实体瘤开展临床试验。2025年前三季度，上海医药实现收入2150.72亿元，归母净利润51.47亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624663631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","BK0184","BK0188","BK0209","BK0099","BK0020","BK0012","BK0187","BK1197","BK0175","BK0196","BK0028","02607","150258","BK0183","BK0097"],"gpt_icon":0},{"id":"2604286379","title":"每周股票复盘：上海医药（601607）收购财务公司10%股权完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2604286379","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604286379?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:21","pubTimestamp":1768670468,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，上海医药报收于17.36元，较上周的17.88元下跌2.91%。本周关注点公司公告汇总：上海医药完成收购上海上实集团财务有限公司10%股权，持股比例升至40%。2025年7月25日，上海医药第八届董事会第二十三次会议审议通过收购上海上实集团财务有限公司10%股权的议案，拟以自有资金约1.43亿元收购上实东滩持有的财务公司10%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0097","BK0183","BK0099","BK1197","BK0020","BK0184","BK0028","BK0196","BK0188","BK0209","BK0175","02607","BK0187","BK0012"],"gpt_icon":0},{"id":"2603762140","title":"上海医药：已完成收购上实集团财务公司10%股权 持股权比例增加至40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603762140","media":"中金财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603762140?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:07","pubTimestamp":1768442822,"startTime":"0","endTime":"0","summary":"中国网财经1月15日讯 昨日，上海医药 发布相关公告披露，截至2026年1月12日，公司与上海实业东滩投资开发(集团)有限公司、上海上实集团财务有限公司已共同申请办理并完成股权变更登记手续，且公司已按照《股权转让协议》的约定向上实东滩一次性支付全部股权转让对价，公司持有上实集团财务公司的股权比例由30%增加至40%，未导致公司合并报表范围发生变更。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260115/31944176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0020","02607","BK0028","BK0012","601607","BK0183","BK0187","BK0209","BK0175","BK0188","BK0099","BK0097","BK0196","BK1197","BK0184"],"gpt_icon":0},{"id":"2603550741","title":"上海医药(02607)完成收购财务公司10%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2603550741","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603550741?lang=zh_cn&edition=full","pubTime":"2026-01-13 18:06","pubTimestamp":1768298771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，内容有关公司由上实东滩收购财务公司10%股权(本次收购)。于2026年1月12日，本次收购已依据该等公告内披露的股份转让协议所载主要条款及条件完成。于本公告日期，公司直接持有财务公司40%股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","02607","BK0187","BK0175","601607","BK0012","BK0097","BK0183","BK0196","BK0099","BK0209","BK0028","BK0184","BK0188","BK0020"],"gpt_icon":0},{"id":"2603505056","title":"上海医药(601607.SH)：硫酸艾沙康唑原料药上市申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2603505056","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603505056?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:49","pubTimestamp":1768290567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药康丽(常州)药业有限公司(以下简称“上药康丽”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于硫酸艾沙康唑原料药(以下简称“该药物”)的《化学原料药上市申请批准通知书》(证书编号：2025YS01127)，该药物获得批准生产。本次硫酸艾沙康唑原料药获得《化学原料药上市申请批准通知书》，表明该原料药符合国内药品注册的有关规定要求，可以在国内市场进行销售，同时为公司后续开展原料药申报积累了宝贵的经验。上述事项不会对公司当期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0184","BK0012","BK0020","BK0209","601607","BK0188","BK0099","BK0187","BK0175","BK0196","BK0183","BK0097","02607","BK1197"],"gpt_icon":0},{"id":"2602744535","title":"每周股票复盘：上海医药（601607）溴吡斯的明口服液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2602744535","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602744535?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:20","pubTimestamp":1768072816,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，上海医药报收于17.88元，较上周的17.86元上涨0.11%。本周关注点公司公告汇总：溴吡斯的明口服溶液获国家药监局批准生产，国内尚无其他企业上市该品种。上海医药集团股份有限公司下属上海上药中西制药有限公司的溴吡斯的明口服溶液获得国家药品监督管理局批准生产，药品注册分类为化学药品3类，规格为473ml：5.676g，批准文号为国药准字H20256499。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1197","BK0099","BK0175","BK0187","BK0020","02607","BK0012","BK0196","BK0209","BK0184","BK0028","BK0183","601607","BK0097"],"gpt_icon":0},{"id":"2602325106","title":"上海医药：溴吡斯的明口服溶液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2602325106","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602325106?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:38","pubTimestamp":1767947913,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月9日，上海医药(601607.SH)公告称，公司下属上海上药中西制药有限公司的溴吡斯的明口服溶液收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。溴吡斯的明口服溶液用于治疗重症肌无力，最早由BAUSCH公司研发，于1965年在美国上市。2024年4月，上药中西就该药品向国家药监局提出注册上市申请，并获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601093614241842.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614241842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0196","BK0188","BK0184","BK1197","BK0020","BK0209","BK0097","BK0099","BK0175","601607","BK0183","BK0187","BK0028","02607"],"gpt_icon":0},{"id":"2600356870","title":"每周股票复盘：云南白药（000538）预计2026年与上海医药关联交易达19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600356870","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600356870?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:44","pubTimestamp":1767289454,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：云南白药预计2026年与上海医药日常关联交易总额为190,000.00万元。预计2026年与上海医药日常关联交易总额为190,000.00万元，占公司最近一期经审计净资产的4.89%，无需提交股东会审议。2025年实际发生关联交易总额为109,929.20万元，未超审批额度。关于2026年度预计日常关联交易的公告云南白药预计2026年度与上海医药发生日常关联交易总额为190,000.00万元，其中向其采购商品预计120,000.00万元，销售商品预计70,000.00万元，交易价格参照市场价格协商确定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0099","02607","BK0028","BK0097","LU1993786604.SGD","BK0196","BK0175","BK1197","LU1807302812.USD","BK0183","LU1960683339.HKD","000538","BK0187","601607","BK0020","BK0012","BK0164","BK0184","BK0188","BK0209"],"gpt_icon":1},{"id":"2595745414","title":"上海医药拟与云南白药续签关联交易协议，2026年双向交易额上限19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595745414","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595745414?lang=zh_cn&edition=full","pubTime":"2025-12-31 08:05","pubTimestamp":1767139521,"startTime":"0","endTime":"0","summary":"中访网数据 上海医药集团股份有限公司于2025年12月29日召开董事会，审议通过了与关联方云南白药集团股份有限公司续签《日常关联交易/持续关连交易框架协议》的议案。根据协议，在2026年1月1日至2026年12月31日期间，上海医药向云南白药销售产品的金额上限为人民币12亿元，向云南白药采购产品的金额上限为人民币7亿元，双向交易总额上限合计19亿元。云南白药目前持有上海医药17.95%的股份，为其第二大股东，构成关联关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251231/31906320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","LU1993786604.SGD","BK1197","BK0175","BK0099","LU1960683339.HKD","BK0239","BK0164","000538","BK0028","02607","BK0188","BK0097","BK0183","601607","BK0196","BK0184","BK0187","BK0020","LU1807302812.USD","BK0209"],"gpt_icon":0},{"id":"2595783594","title":"上海医药拟与云南白药续签19亿元上限关联交易协议，销售采购双向合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2595783594","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595783594?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:22","pubTimestamp":1766996528,"startTime":"0","endTime":"0","summary":"12月29日，上海医药（601607/02607）发布公告，公司拟与云南白药（000538）续签日常关联交易/持续关连交易框架协议。根据协议，2026年公司向云南白药销售产品金额上限为12亿元，向云南白药采购产品金额上限为7亿元。云南白药持有公司17.95%的股份，为公司第二大股东，是公司的关联方。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604442415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0184","BK0196","BK0020","BK0028","000538","BK1197","BK0099","LU1960683339.HKD","BK0188","BK0187","LU1993786604.SGD","601607","BK0239","BK0097","BK0209","02607","BK0012","BK0175","BK0183","LU1807302812.USD","BK0164"],"gpt_icon":0},{"id":"1145701636","title":"上海医药拟续签云南白药框架协议 2026年销售上限12亿元、采购上限7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145701636","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145701636?lang=zh_cn&edition=full","pubTime":"2025-12-29 15:58","pubTimestamp":1766995115,"startTime":"0","endTime":"0","summary":"，中文，长度不超过4096字符，这里肯定没问题。检查是否符合所有要求：股票名称正确，关键信息保留，改写后流畅，有节奏感，无语法错误，中文表达自然。上海医药宣布，公司计划与云南白药续签框架协议。根据协议安排，2026年上海医药对云南白药的销售额上限将设定为12亿元，同期向云南白药的采购额上限则为7亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0183","LU1993786604.SGD","BK0188","BK0164","BK0012","BK0196","LU1807302812.USD","BK0028","000538","BK0187","BK0099","BK0209","BK0184","BK0020","BK0239","601607","BK0097","LU1960683339.HKD"],"gpt_icon":0},{"id":"2595669201","title":"上实集团财务公司股权变更获批 上海医药合计持股比例达40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595669201","media":"中国网财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595669201?lang=zh_cn&edition=full","pubTime":"2025-12-29 13:20","pubTimestamp":1766985655,"startTime":"0","endTime":"0","summary":"中国网财经12月29日讯今日，上海金融监管局发布相关批复，同意上海医药集团股份有限公司(简称“上海医药”)受让上海实业东滩投资开发(集团)有限公司(简称“上实东滩”)持有的上海上实集团财务有限公司(简称“上实集团财务公司”)10%股权。受让后，上海医药合计持有上实集团财务公司40%股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512293604337474.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604337474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0099","BK0183","BK0184","02607","BK0187","BK0012","BK0188","601607","BK0020","BK1197","BK0209","BK0196","BK0097","BK0028"],"gpt_icon":0},{"id":"2594244029","title":"每周股票复盘：上海医药（601607）每股派现0.12元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244029?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:29","pubTimestamp":1766863750,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，上海医药报收于17.86元，较上周的18.03元下跌0.94%。12月24日盘中最低价报17.83元。上海医药当前最新总市值662.31亿元，在医药商业板块市值排名1/32，在两市A股市值排名267/5178。本周关注点公司公告汇总：上海医药2025年半年度每股派发现金红利0.12元（含税）。本次利润分配以公司总股本3,708,361,809股为基数，共派发现金红利445,003,417.08元，其中A股现金红利334,714,692.60元。A股股东的红利由中国结算上海分公司或公司自行发放，H股股东分红情况详见港交所公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK1197","BK0183","02607","BK0188","601607","BK0187","BK0209","BK0028","BK0099","BK0196","BK0184","BK0175","BK0020","BK0012"],"gpt_icon":0},{"id":"2594263071","title":"建发致新：目前医疗器械SPD管理业务主要竞争对手有国药集团、上海医药、华润医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2594263071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594263071?lang=zh_cn&edition=full","pubTime":"2025-12-26 11:36","pubTimestamp":1766720166,"startTime":"0","endTime":"0","summary":"证券之星消息，建发致新(301584)12月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司spd 系统，目前竞争对手有哪几家，份额占比多少建发致新回复：你好，尊敬的投资者。目前医疗器械SPD管理业务行业主要竞争对手有国药集团、上海医药、华润医药等医药商业企业，除此之外存在部分SPD专业管理公司如国医科技、德荣医疗、塞力医疗等。市场份额方面，根据部分市场报告显示，国药集团目前居于行业主导地位，其余公司呈现分散竞争的格局。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600012621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","159883","BK1570","03320","301584","BK1191","601607","BK0209","BK0196","BK0184","BK1583","BK0175","BK1574","09997","BK0188","BK0020","BK0097","BK0028","BK1222","BK0250","BK0187","BK1100","09996","BK0012","BK1197","BK0099","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769748777851,"stockEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0158},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0913},{"period":"1year","weight":-0.1162},{"period":"ytd","weight":-0.018}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0514},{"period":"6month","weight":0.168},{"period":"1year","weight":0.2791},{"period":"ytd","weight":0.0477}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}